Aktive Positionen von Ray Takigiku
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Bexion Pharmaceuticals, Inc.
 Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | Technik-/Wissenschafts-/F&E-Leiter | 02.02.2022 | - |
| Gründer | 01.01.2006 | - | |
| Direktor/Vorstandsmitglied | 01.01.2006 | - | |
| Vorstandsvorsitzender | 01.01.2006 | 02.02.2022 | |
| Präsident | 01.01.2006 | 02.02.2022 | |
Sidis Corp
 Sidis Corp Financial ConglomeratesFinance Sidis Corp provides investment services for market-leading life science companies. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Ray Takigiku
Statistik
International
| Vereinigte Staaten | 3 |
Operativ
| Director/Board Member | 2 |
| Chief Executive Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Commercial Services | 2 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | Commercial Services |
Sidis Corp
Sidis Corp Financial ConglomeratesFinance Sidis Corp provides investment services for market-leading life science companies. | Finance |
- Börse
- Insiders
- Ray Takigiku
- Erfahrung